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An attempt at assessing the efficacy of combined positron emision tomography
and computed tomography (PET/CT) imaging in the diagnosis of pancreatic
carcinoma – own experiences
Zbigniew Kula1, Jaros∏aw Szefer2, Tomasz Pietrzak2, Zdzis∏aw Zuchora2
I n t r o d u c t i o n.  Positron emission tomography (PET) with the use of fluoride-18-fluorodeoxyglucose (FDG) is one of the
most modern methods of obtaining a functional image of the entire body, the trunk or a selected organ. In case of oncological
diagnosis the method bases upon the phenomenon that neoplastic cells show an increased uptake of glucose. Thus, glucose
is labeled with a positron radioisotope, which allows for tumour imaging. When FDG-PET is combined with CT scanning the
efficacy of the method is enhanced.
A i m.  To perform a retrospective analysis of the clinical value of PET/CT for the diagnosis of suspected pancreatic tumours
or postoperative pancreatic tumour recurrence.
M a t e r i a l  a n d  m e t h o d.  Between march 2003 and December 2004 PET/CT was performed in 22 patients (13 men, 9
women; mean age 55.9 yrs) with diagnosed or suspected pancreatic cancer (in 11 cases the pancreatic tumour was found in
the course of other imaging examinations, in 5 cases there was a distinct suspicion of a pancreatic tumour, but the imaging
examinations were negative, and in the remaining 6 cases there was a distinct suspicion of postoperative pancreatic tumour
recurrence)
R e s u l t s.  In all the 11 patients with pancreatic tumours we discerned foci of increased glucose utilization (increased FDG
uptake). PET/CT provided data to diagnose pancreatic tumours with a high probability in 2 cases. In the case of the
remaining patients it was impossible to differentiate between pancreatic cancer and chronic pancreatitis. In 4 cases the
results of PET/CT suggested that the local advancement of the malignant process was lesser than that recognized
intraoperatively. In 5 patients, in whom pancreatic cancer was suspected although no tumour mass had been diagnosed in the
course of other imaging analyses, the results of the PET/CT were unequivocal. In 4 out of the 6 postoperative patients we
diagnosed recurrence in the form of distant metastases.
C o n c l u s i o n.  PET/CT scanning may have significant clinical value in the early diagnosis of postoperative recurrence of
pancreatic cancer and in the diagnosis of distant metastases. Its clinical value for the differentiation between pancreatic cancer
and pancreatitis and for the evaluation of the local advancement of pancreatic cancer is probably lesser.
Próba oceny po∏àczenia pozytonowej tomografii emisyjnej z tomografià komputerowà (PET/KT)
w rozpoznawaniu raka trzustki – doÊwiadczenia w∏asne
W s t ´ p.  Pozytonowa tomografia emisyjna (PET) z u˝yciem F-18-fluorodeoksyglukozy (FDG) nale˝y do najnowszych
metod czynnoÊciowego obrazowania ca∏ego cia∏a, tu∏owia lub wybranego narzàdu. W diagnostyce onkologicznej metoda
wykorzystuje zwi´kszony wychwyt glukozy znakowanej radioizotopem pozytonowym przez komórki nowotworowe. Po∏àczenie
skanerów FDG-PET i tomografii komputerowej (KT) zwi´ksza mo˝liwoÊci diagnostyczne badania.
C e l  p r a c y.  Retrospektywna ocena wartoÊci klinicznej badania PET/KT u chorych z podejrzeniem raka trzustki lub
wznowy raka trzustki po operacji.
M a t e r i a ∏  i m e t o d a.  Badanie PET/KT wykonano u 22 chorych (9 kobiet, 13 m´˝czyzn, Êredni wiek 55,9 lat) od marca
2003 r. do grudnia 2004 r. U 11 chorych wskazaniem do badania by∏ guz trzustki stwierdzony w badaniach obrazowych, u 5
chorych podejrzenie raka trzustki bez stwierdzonego guza w badaniach obrazowych, a u 6 chorych podejrzenie nawrotu
raka trzustki po operacji.
W y n i k i.  Ogniska wzmo˝onej utylizacji glukozy (wychwytu FDG) stwierdzono u wszystkich 11 chorych z guzem trzustki.
Badanie PET/KT u dwóch chorych pozwoli∏o z du˝ym prawdopodobieƒstwem rozpoznaç raka trzustki. W pozosta∏ych
przypadkach ró˝nicowanie raka i zapalenia trzustki by∏o niepewne. W 4 przypadkach wynik badania PET/KT wskazywa∏ na
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Pancretaic cancer (PC) is rarely curable and presents
as one of the main causes for cancer mortality throughout
the world. Overall 5-year survival ranges between 3%
and 5%, while a vast majority of patients (80-85%) are
disqualified from surgical treatment on diagnosis [1]. In
Poland in the year 2000 1917 men and 1847 women died
of PC; while the number of PC deaths has increased four
times over the last 35 years [2]. In view of these facts it is
obvious that early diagnosis is of crucial importance for
patient survival, although it is still very difficult to achieve
it despite the application of numerous modern methods
of imaging. As for now we are not in the possession
of a PC-specific marker, while the applicability of the
CA 19-9 carbohydrate antigen is limited. Potential risk
factors, which could be used in the course of screening,
are also unclear, with the exception of hereditary
pancreatitis. Different diagnostic methods, such as abdo-
minal ultrasound (USG), computed tomography (CT),
magnetic resonance imaging (MRI), magnetic resonance
cholangiopancreatography (MRCP), endoscopic ultra-
sound (EUS), endoscopic retrograde cholangiopan-
creatography (ERCP), EUC-guided fine needle aspiration
biopsy and transcutaneous fine needle aspiration biopsy
all have sub-optimal sensitivity, specificity and diagnostic
accuracy and therefore unclear or erroneous diagnoses
are common.
Positron emission tomography (PET) is one of the
most modern imaging methods. It may be performed
after intravenous administration of a radioisotope, which
emits positron radiation. In the course of oncological
diagnostics the method bases upon the fact, that
malignant cells show increased glucose utilization as
compared to healthy tissue cells. The most common
radiopharmaceutical preparation used in PET is a glucose
derivative called fluoride-18-fluorodeoxyglucose (FDG)
and therefore the term PET relates to PET with FDG,
while PET performed with any other radioisotope must
be specifically named. The increased uptake of FDG
(which behaves exactly like glucose within the cell until it
enters the phosphorilation stage) shown by neoplastic
cells allows registering positron radiation in the places
where the isotope is pathologically accumulated. Early
studies have shown the high clinical value of PET for the
diagnosis of pancreatic lesions, but the more recent
publications are not equivocal [3-5]. One may expect an
increased clinical efficacy of PET if it were combined
with CT scanning. The fusion of the images allows
performing a functional and anatomical survey of the
entire body in the course of one non-invasive exami-
nation. Until now it has not been concluded whether
PET/CT may be helpful in the diagnosis of PC, including
its efficacy for the differentiation between cancer and
chronic pancreatitis.
The aim of this study was to perform an initial,
retrospective analysis of PET/CT in patients suspected
of primary PC and for the diagnosis of postoperative PC
recurrence.
Material and method
We performed a retrospective analysis of 22 patients (13 men, 9
women) who had, between March 2003 and December 2004,
undergone PET/CT scanning for primary PC or postoperative
PC recurrence at the Department of Nuclear Medicine of the
Center of Oncology in Bydgoszcz. Patient age varied between 19
and 78 yrs (mean age 55.9 yrs)
In 11 cases the pancreatic tumour was found in the course
of other imaging examinations, in 5 cases there was a distinct
suspicion of a pancreatic tumour but the imaging examinations
were negative, and in the remaining 6 cases there was a distinct
suspicion of postoperative pancreatic tumour recurrence. The
PET/CT was performed with a Biograph scan (Siemens) 60-90
minutes after the intravenous administration of approx.
370 MBq of FDG. FDG could only be applied if the blood
glucose level was <8.4 mmol/l. After the administration of FDG
the patient rested for 1 hour, over which he or she had to drink
1 litre of mineral water. The PET/CT scan was performed
between two lines – the upper at the level of the eyeballs and the
lower directly below the buttocks. The standard uptake value
(SUV) was calculated according to the following equation:
SUV =
tissue concentration (millicuries / g)
injection dose (millicuries) / body weight (g)
The results were interpreted in three categories: high likelihood
of PC (+); unequivocal results (+–) and low likelihood of PC
(–). We also performed a detailed analysis of the patients’
histories noting the results of USG, CT, MRCP, ERCP, histo-
pathological analyses (HP), chest X-ray (RTG), follow-up and
therapies. After some 6-18 months (mean 11.5 months) from
the time of the PET/CT we were able to perform an analysis
of the clinical value of the obtained results.
Results
PET/CT scanning presented foci of increased FDG
uptake in all 11 patients in whom a pancreatic tumour
had been discerned in the course of other imaging
examinations (Figure 1). In two cases the diagnosis of
PC was highly probable, while in 1 case the results of the
PET/CT were suggestive of a benign process. In the
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mniejsze zaawansowanie miejscowe raka trzustki ni˝ stwierdzone badaniem Êródoperacyjnym. U 5 chorych z podejrzeniem raka
trzustki bez masy guza w badaniach obrazowych wynik badania PET/KT by∏ niejednoznaczny. U 4 z 6 chorych po leczeniu
operacyjnym rozpoznano wznow´ raka trzustki, w tym u wszystkich przerzuty odleg∏e.
W n i o s k i.  Badanie PET/KT mo˝e mieç du˝à wartoÊç klinicznà we wczesnym rozpoznaniu wznowy raka trzustki po operacji
oraz w diagnostyce przerzutów odleg∏ych. Badanie PET/KT prawdopodobnie ma mniejszà wartoÊç klinicznà w ró˝nicowaniu
raka i zapalenia trzustki oraz w ocenie miejscowego zaawansowania raka trzustki.
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remaining case we found the results of the PET/CT to
be unequivocal. Basing upon clinical observation, the
results of additional analyses (RTG, USG, CT, MRI,
MRCP and HP) and intraoperative examination PC was
finally confirmed in 7 cases. In two patients with
confirmed PC the results of the PET/CT were uniform
with the advancement of the disease, as discerned
intraoperatively. In the remaining four cases disease
advancement was in fact greater than the PET/CT
findings had suggested and radical surgical treatment was
impossible (allowing only for explorative laparotomy
and/or cholangio-duodenic anastomosis). In three cases
intraoperative examination allowed to diagnose an
inflammatory tumour, which was resected in 1 case in
the course of distal pancreatectomy (Figure 2). In one
patient we performed PET/CT 1 hour and 2 hours after
the administration of FDG, but we failed to observe
a SUV increase in the course of the second hour. In this
case follow-up brought the diagnosis of inflammatory
pancreatic tumour. The characteristics of the patients
undergoing PET/CT with the previous diagnosis of
a pancreatic lesion are presented in Table I.
The second analysed group consisted of the 6
patients with a distinct suspicion of PC, but without
a discernible pancreatic lesion observed in the course of
other examinations. In all of these patients the results of
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Figure 1. 78-year old man (10) with diagnosed pancreatic carcinoma.
Transaxial PET/CT imaging of the abdominal cavity. In the projection
of the pancreatic head – an area of increased FDG uptake analogous
to pancreatic carcinoma
Figure 2. 45-year old man (09) with diagnosed inflammatory
pancreatic tumour. Transaxial PET/CT imaging of the abdominal
cavity. In the projection of the pancreatic head – presence of focal
FDG uptake analogous to an inflammatory pancreatic tumour
Table I. PET/CT imaging results in 11 patients with pancreatic tumours diagnosed by means of USG, CT, MRI and MRCP
No Age Gender Size of lesion PET SUV Treatment Histopathology
in imaging diagnostics [mm] results results
(USG, CT, MRI, MRCP)
01 47 M 38x49x51 (+ -) 6.1 cholecystectomy inflammation
02 48 M 38x25x34 (-) 6.1 modo Whipple adenocarcinoma
03 19 M 22x23x18 (+) 2.4 follow-up inflammation
04 70 F 44x52x48 (+) 9.2 laparotomy adenocarcinoma
05 45 M 42x46x44 (-) 2.6 laparotomy inflammation
06 63 M 45x60x56 (+ -) 5.3 laparotomy adenocarcinoma
07 53 M 29x28x30 (+ -) 4.0 laparotomy adenocarcinoma
08 49 F 42x36x48 (+ -) 9.6 laparotomy adenocarcinoma
09 45 M 15x16x15 (+ -) 3.0 peripheral inflammation
pancreatectomy
10 78 M 38x29x53 (+) 10.5 modo Traverso adenocarcinoma
11 57 K 23x30x25 (+ -) 2.8 peripheral adenocarcinoma
pancreatectomy
Explanation: high probability (+), equivocal result (+ -), low pancreatic cancer probability (-)
the PET/CT were unequivocal. In one patient we did find
a focus of increased FDG uptake within the head of the
pancreas (SUV 10.1), yet the result was pronounced as
unequivocal due to the presence of a stent within the bile
ducts; the results of fine needle aspiration biopsy
confirmed a malignant process. In the remaining 4
patients chronic pancreatitis was diagnosed in the course
of follow-up. The characteristics of the patients under-
going PET/CT with a previous suspicion of PC but
without the presence of a pancreatic lesion in other
imaging examinations are presented in Table II.
The third analysed group consisted of 6 patients with
a suspicion of postoperative recurrence of PC. In 4 cases
PET/CT provided data confirming recurrence in the form
of numerous foci of increased FDG uptake within the
lungs, the spine, the retroperitoneal space, the pelvis and
the abdominal wall (Figure 3 and 4). One person was
qualified for surgical treatment – the resection of a single
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Table II. PET/CT imaging results in 5 patients with suspected pancreatic carcinoma – USG, CT, MRI 
and ERCP examinations without tumour presence
No Age Gender Imaging diagnostics PETnik SUV Localisation of Therapy Final
(USG, CT, MR, ERCP) results lesions diagnosis
01 72 M stenosis and modelling (+ -) 5.3 head of bile acute
of the choledochus the pancreas duct pancreatitis
prosthesis
02 34 F hypoechogenic tail (+ -) 4.2 whole BAC inflammation
and body of pancreas ascites pancreas follow-up cirrhosis
03 56 F dilated bile ducts (+ -) 10.1 head of BAC adenocarcinoma
blurred head of pancreas the panccreas prosthesis 
04 53 F blurred contours (+ -) 1.1 sphincterectomy acute
enlarged tail of pancreas pancreatitis
05 53 M nonhomogenous (+ -) 3.5 head follow-up chronic
echogenic pancreas fibrosis tail of pancreas pancreatitis
Explanation: high probability (+), equivocal result (+ -), low pancreatic carcinoma probability (-)
Figure 3. 59-year old woman (06) with diagnosed local pancreatic
carcinoma recurrence and pulmonary metastases. Transaxial PET/CT
imaging of the abdominal cavity. At the site of the pancreatic cancer –
presence of focal FDG uptake analogous to local recurrence
Figure 4. 59-year old woman (06) with diagnosed local pancreatic carcinoma recurrence and
pulmonary metastases. Transaxial PET/CT images of the thorax. Presence of focal FDG uptake in the
right lung – analogous to a metastasis of pancreatic carcinoma. Local FDG uptake by the liver
metastatic tumour from the anterior wall of the abdomen;
in the remaining 3 cases dissemination was confirmed.
The characteristics of the patients undergoing PET/CT
postoperatively are presented in Table III.
Discussion
PET is becoming more and more popular in the diagnosis
and treatment of malignancies. In the case of malignant
tumours of the alimentary tract PET is especially useful in
the diagnosis and evaluation of postoperative recurrences
of colorectal cancer and in the early diagnosis of
esophageal cancer. The value of PET in the early
diagnosis of PC has been, initially, enthusiastically
commented. In an analysis of 106 patients with a patho-
logical mass within the pancreas Zimny et al. evaluated
the sensitivity and specificity of PET as 85% and 84%,
respectively [6], while Delbece et al. in a study of 65
patients with a strong suspicion of PC have shown
a significantly higher sensitivity and specificity of PET
(92% and 85% respectively), as compared to CT (65%
and 61%) [7]. A similar study has also been conducted by
Sperti et al. who have shown higher sensitivity and
specificity of PET (94% and 97%, respectively) as
compared to CT (65% and 87%) [8]. To summarise –
the first studies on the applicability of PET in the
differentiation of PC and pancreatitis have shown the
diagnostic accuracy of PET to exceed 85%. However,
more recent studies question these results – especially
for the differentiation of malignant and benign lesions
within the pancreas. In a prospective study Sendler at al.
have shown a low sensitivity (75%) and specificity (64%)
of PET in the diagnosis of PC and a poor diagnostic
accuracy in the differentiation of pancreatic tumours
(69%) [3]. In a number of patients PET scanning was
performed after previous invasive procedures, which
could have increased the ratio of false positive results.
Higashi et al. have shown, in a study of 53 patients, that in
the course of differentiating benign and malignant lesions
PET has a relatively low sensitivity (65%) while it possess
higher specificity (93%) and clinical accuracy (81%). In
our study it was possible to recognize a tumour, which
had been previously diagnosed in the course of other
imaging methods, only in two cases. Due to the small
number of patients we refrained from analyzing the
sensitivity, the specificity and the clinical accuracy of this
method.
We would like to stress that not a single one of the
present-day imaging methods allows for a positive
differentiation between PC and chronic pancreatitis. Final
diagnosis can only be made in the course of histo-
pathological analysis of surgically harvested tissue
samples. In the case of PET the limitations arise from
the fact that the cells within the inflammatory infiltration
have an increased glucose uptake, resembling that
observed in malignant cells. It is assumed that some 24%
of the total FDG accumulation within a malignant tumour
has been carried out buy the inflammatory cells [9]. Also
the accumulation pattern of the radioisotope is not much
help in the differentiative diagnostics, because both the
inflammatory and the malignant infiltrations may be
either localized or disseminated throughout the entire
organ. In order to differentiate between PC and chronic
pancreatitis one may analyse the quantitative radioactivity
of accumulated FDG. Due to the fact that our patient
group was rather small we could not arrive at any
statistically confirmed conclusions, but we believe that
high mean SUV may be characteristic of malignant
lesions. Nitzsche et al. have improved their results by
performing dynamic PET scanning with an analysis of
the uptake curve in relation to time [10]. In the case of PC
the FDG uptake curve rises rapidly in the final phase, as
compared to the shape of the curve in the case of patients
with benign lesions. These observations may be supported
further by the case of our one patient with a benign
tumour within the head of the pancreas, in whom we had
performed PET 1 hr and 2 hrs after the administration of
FDG. When analyzing SUV one must, however, keep in
mind that they vary significantly depending upon the
duration of the scan, the size and structure of the tumour
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Table III. PET/CT imaging results in 6 patients with suspicion of local recurrence 
or pancreatic carcinoma metastases after surgical treatment
No Age Gender Type Imaging results PET SUV Localisation Final diagnosis
of operation (USG, CT, MRI) result of recurrence
01 64 M Traverso no lesions (+ -) 6.1 oesophagus no recurrence
02 72 M Whipple irregular lesion (+) 5.5 anterior metastasis
47x30 mm in the rectus abdominal
abdominis muscle wall
03 52 F Whipple hepatic focal (+) 11.8 pelvis metastasis
lesions liver
04 54 F Whipple enlarged (+ -) 3.0 nodal metastases
paramesenteric nodes spine
05 72 F Traverso no lesions (+ -) 4.8 mediastinum no recurrence
06 59 F Whipple pulmonary (+) 3.2 lungs metastases
lesions (+ -) 2.8 tumour site local recurrence
Explanation: high probability of recurrence (+), equivocal result (+ -), low probability of pancreatic carcinoma recurrence
and upon the blood glucose and insulin concentrations.
We believe that high SUV allows for diagnosing PC with
a high probability, especially in view of the overall clinical
data, increased levels of CA 19-9 and the results of other
imaging techniques. In our opinion PET/CT scanning
may, despite the listed limitations, be a very useful
diagnostic tool in the differentiation of PC and chronic
pancreatitis, especially in combination with other
diagnostic methods.
An analysis of 5 patients with diffuse abnormalities
within the pancreas and a concomitant pathology within
the bile ducts has allowed us to conclude that in such
cases the differentiative diagnosis of PC also has
a number of limitations. PET results may suggest the
presence of a malignancy especially in patients with acute
or chronic pancreatitis and in the case of choledochitis
and/or choledocholithiasis. The false positive result may
also be caused by previous invasive techniques (ERCP
and BAC) and endoscopic procedures (sphincterectomy,
prosthesis of the bile ducts and the pancreatic ducts).
The basic aim of modern-day diagnostics is the early
recognition of a malignant lesion and an exact analysis of
clinical advancement. The value of PET in PC is best
observed in the case of discerning distant metastases. A
few studies have shown that the diagnostic accuracy of
PET in the recognition of hepatic metastases is higher
than that of CT and abdominal USG [11-13]. Frohlich
et al. report that the frequency of the recognition of
hepatic focal lesions over 10 mm in diameter is 97% with
PET, while in the case of lesser lesions it reaches 43%
[13]. In the case of hepatic metastases, which are
characterized by an avid glucose uptake, the lesions may
be considered larger than they in fact are [4]. In the case
of lymph node metastases the value of PET is much
smaller. Although in the course of the initial studies
lymph node metastases were recognized in some 76% of
patients [11], more recent reports have shown the clinical
accuracy of PET to pose itself between 46% to 56% [4, 6].
Basing upon our material we may also say that in the
case of lymph node metastases the specificity of PET/CT
is too poor, especially in the case of parapancreatic nodes.
Presently, it is assumed that the most exact method of
preoperative evaluation of the advancement of PC (i.e.
the infiltration of neighbouring organs and large vessels)
is EUS [14-16]. Martz et al. [14] have shown, that
combined EUS and PET have a higher sensitivity in PC
staging than spiral CT. In our patient material in the case
of 4 patients the results of PET/CT were characteristic of
a lesser local advancement, than that found intra-
operatively, i.e. in those cases the results of PET/CT did
not allow us to refrain from unnecessary laparotomies.
Higasthi et al. have found distant metastases and other
primary malignancies in 35/132 patients (38%) evaluated
with PET for the advancement of PC [4] and they believe
that PET scanning performed for the evaluation of the
advancement of PC allows to alter the planned treatment
course in some 40% of patients. In our patient group this
ratio was much smaller while PET/CT influenced the
treatment course only in combination with the results of
other examinations and of the overall clinical picture.
Studies on small patients groups have proven the
high clinical value of PET for the diagnosis of PC
recurrence after surgery. As in the case of colorectal
cancer, PET scanning allows for the earliest possible
diagnosis of PC in the case of an increase in the activity of
markers of malignancy with concomitant negative results
of other methods of diagnostic imaging. Our results
regarding the 4 patients with PC recurrence confirm these
results – this is true both in the case of distant and local
failure. Our early experiences show that PET/CT may
have significant clinical value in the early recognition of
postoperative local failure in PC and in the diagnosis of
distant metastases. PET/CT is less effective in the
differentiation of PC, and chronic pancreatitis, and for the
sake of the evaluation of local advancement of PC. In
the latter cases PET/CT may be considered as auxiliary
method accompanying other diagnostic procedures. Our
results indicate the need for further prospective studies on
larger patient groups, including PET/CT scanning with
the evaluation of radioactivity over a longer time period.
We believe that as PET is replaced with PET/CT and
new scanners and radiomarkers are introduced the clinical
value of this diagnostic modality in patients with PC will
increase.
Zbigniew Kula MD, PhD
Gastroenterology & Endoscopy Outpatient Clinic
The Franciszek ¸ukaszczyk Center of Oncology
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